Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Many approaches have been taken to identify new biomarkers of pancreatic ductal carcinoma (PDC). Since animal models can be sampled under controlled conditions, better standardization is possible compared with heterogeneous human studies. Transgenic rats with conditional activation of oncogenic RAS in pancreatic tissue develop PDC that closely resembles the biological and histopathological features of human PDC. Using this model, we evaluated the usefulness of leucine-rich α2-glycoprotein-1 (LRG-1) as a serum marker. In this study, we found that LRG-1 was overexpressed in rat PDC compared with normal pancreas tissue of the control rats. Serum levels of LRG-1 were also significantly higher in rats bearing PDC than in controls. Importantly, chronic pancreatitis in male Wistar Bonn/Kobori rats, which is a widely accepted as a model of chronic pancreatitis, did not cause serum levels of LRG-1 to become elevated. These results strongly support serum LRG-1 as a candidate biomarker for noninvasive diagnosis of PDC. Our models of pancreas cancer provide a useful strategy for evaluation of candidate markers applicable to human cancer.

Cite

CITATION STYLE

APA

Fukamachi, K., Hagiwara, Y., Futakuchi, M., Alexander, D. B., Tsuda, H., & Suzui, M. (2019). Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model. Journal of Toxicologic Pathology, 32(3), 135–141. https://doi.org/10.1293/tox.2018-0062

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free